Kanda Tatsuo, Nakamura Masato, Yasui Shin, Haga Yuki, Tawada Akinobu, Suzuki Eiichiro, Ooka Yoshihiko, Takahashi Koji, Sasaki Reina, Wu Shuang, Nakamoto Shingo, Arai Makoto, Imazeki Fumio, Yokosuka Osamu
Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan.
Safety and Health Organization, Chiba University, 1-33 Yayoicho, Inage-ku, Chiba 263-8522, Japan.
Biology (Basel). 2017 May 9;6(2):30. doi: 10.3390/biology6020030.
The aim of this study was to characterize the treatment response and tolerability of sofosbuvir plus ribavirin therapies in Japanese patients infected with hepatitis C virus (HCV) genotype (GT)-2. This retrospective study analyzed 114 Japanese HCV GT-2 patients treated for 12 weeks with 400 mg of sofosbuvir plus weight-based ribavirin daily. This treatment led to higher sustained virologic response at 12-weeks post-treatment (SVR12) rates in both treatment-naïve and treatment-experienced patients. The efficacy of this treatment in compensated cirrhotics was the same as that in patients with chronic hepatitis. HCV GT-2a infection and lower estimated glomerular filtration rates (eGFR) tended to be associated with SVR12. Of 114 patients, 113 completed the combination of sofosbuvir plus ribavirin for 12 weeks. Seven patients without SVR12 did not have HCV NS5B-S282 mutations. The overall SVR12 rate was 90.4% (103 of 114). More effective therapeutic options with less adverse events are desired to achieve higher SVR rates in HCV GT-2 Japanese patients.
本研究的目的是明确索磷布韦联合利巴韦林疗法对日本丙型肝炎病毒（HCV）基因2型（GT-2）感染者的治疗反应及耐受性。这项回顾性研究分析了114例接受400毫克索磷布韦联合基于体重的利巴韦林每日治疗12周的日本HCV GT-2患者。该治疗使初治和经治患者治疗后12周持续病毒学应答（SVR12）率更高。这种治疗对代偿期肝硬化患者的疗效与慢性肝炎患者相同。HCV GT-2a感染和较低的估计肾小球滤过率（eGFR）往往与SVR12相关。114例患者中，113例完成了索磷布韦联合利巴韦林12周的治疗。7例未获得SVR12的患者没有HCV NS5B-S282突变。总体SVR12率为90.4%（114例中的103例）。为了在日本HCV GT-2患者中获得更高的SVR率，需要有更有效的治疗选择且不良事件更少。
